Dermira Inc. (DERM) Director William R. Ringo Sells 500 Shares
Dermira Inc. (NASDAQ:DERM) Director William R. Ringo sold 500 shares of Dermira stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $34.25, for a total value of $17,125.00. Following the sale, the director now directly owns 500 shares in the company, valued at approximately $17,125. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Dermira Inc. (NASDAQ:DERM) opened at 34.77 on Wednesday. The company’s market cap is $1.23 billion. Dermira Inc. has a 1-year low of $17.42 and a 1-year high of $36.16. The stock has a 50 day moving average price of $33.01 and a 200-day moving average price of $29.42.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. Analysts predict that Dermira Inc. will post ($3.39) earnings per share for the current fiscal year.
Several analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 target price on shares of Dermira in a research note on Wednesday, September 21st. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $41.00.
Institutional investors have recently bought and sold shares of the stock. TimesSquare Capital Management LLC boosted its position in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock valued at $72,877,000 after buying an additional 1,101,645 shares during the period. FMR LLC boosted its position in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock valued at $118,847,000 after buying an additional 921,800 shares during the period. Jennison Associates LLC boosted its position in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock valued at $73,539,000 after buying an additional 860,597 shares during the period. Loomis Sayles & Co. L P purchased a new position in Dermira during the second quarter valued at approximately $10,678,000. Finally, Vanguard Group Inc. boosted its position in Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock valued at $27,529,000 after buying an additional 304,750 shares during the period. 82.46% of the stock is owned by hedge funds and other institutional investors.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.